Prophylactic Ketorolac Post Epiretinal Membrane Surgery

A Placebo-controlled, Randomized, Clinical Trial of Prophylactic Ketorolac 0.5% in Patients Undergoing Pars Plana Vitrectomy and Phacovitrectomy Epiretinal Membrane Peel Surgery: Assessing Macular Volume With Spectral-domain OCT

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00974753

Enrollment

Registered

2009-09-10

Start date

2010-03-31

Completion date

2012-03-31

Last updated

2016-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macular Edema

Keywords

epiretinal membrane

Brief summary

Evaluate the efficacy of ketorolac 0.5%, a topical non-steroidal anti-inflammatory drug (NSAID), to prevent macular edema after epiretinal membrane surgery. Patients undergoing epiretinal membrane surgery have increased risk of macular swelling which can adversely affect vision. Since post-intraocular surgery inflammation is a contributing factor to macular swelling and loss of vision, NSAID drops may be able to prevent or minimize the deleterious effects of macular swelling after epiretinal membrane surgery.

Interventions

DRUGKetorolac 0.5%

Four-times a day starting one week before surgery and continued for 4 weeks post surgery.

OTHERSaline drops

Four-times a day starting one week before surgery and continued for 4 weeks post surgery.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

* idiopathic epiretinal membrane diagnosis requiring membrane peel surgery

Exclusion criteria

* proliferative diabetic retinopathy * sickle cell retinopathy * radiation retinopathy * choroidal folds * hypersensitivity or allergy to NSAIDs * wet macular degeneration * branch retinal vein occlusion (BRVO) * central retinal vein occlusion (CRVO) * complicated membrane peel surgery

Design outcomes

Primary

Measure	Time frame
Change in macular volume from baseline.	Before surgery, at 1 week, 1 month, and 1 year after surgery.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026